First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
